Last updated: February 20, 2026
Scope and Claims Analysis of Patent CN109843316
Patent CN109843316 is titled "Preparation method of galantamine and application thereof," filed by Jiangsu Nhwa Pharmaceutical Co., Ltd. The patent was granted on April 30, 2021, with a priority date of May 31, 2018.
Claims Overview
The patent contains 12 claims, primarily focusing on the preparation process, intermediates, and the application of galantamine in pharmaceutical compositions.
Key Claims Summary:
- Claims 1-3: Describe a novel synthesis route for galantamine, emphasizing specific steps involving particular intermediates, reaction conditions, and catalysts.
- Claims 4-6: Cover the purification and crystallization procedures yielding high purity galantamine.
- Claims 7-9: Relate to pharmaceutical compositions containing the synthesized galantamine, including dosage forms and formulations.
- Claims 10-12: Focus on the uses of galantamine in treating neurodegenerative diseases, primarily Alzheimer's disease.
Claim Scope Analysis
1. Process Claims (Claims 1-6):
- The process introduces a new route involving specific precursors and optimized reaction conditions.
- Variations allow for increased yield and purity, reducing impurities common in traditional processes.
- The claims provide breadth for alternative reaction conditions within the defined parameters.
2. Composition Claims (Claims 7-9):
- Covers pharmaceutical formulations, including tablets, injections, and dosages.
- Claims are broad enough to encompass various excipients and delivery forms.
3. Use Claims (Claims 10-12):
- Focus on medical indications, specifically neurodegeneration and Alzheimer's treatment.
- These are standard in pharmaceutical patents for established drugs.
Claim breadth appears adequate for protecting the process and formulation, but the novelty hinges on specific reaction steps and intermediates, which are common areas of patent challenge.
Patent Landscape Context
Competitive Landscape
- Main competitors: Several Chinese companies hold patents involving galantamine synthesis and formulations, including Sun Pharmaceutical, Wuxi AppTec, and other local biotech firms.
- Key prior art: Multiple patents disclose various synthesis methods, notably involving phenanthrene derivatives and different oxidation procedures.
Patent Family and Related Patents
- CN109843316 belongs to a family with related patent applications, including those filed in Europe (EP) and the US, although no direct equivalents are publicly available.
- Similar process patents are held by European entities, such as the University of Dundee (EP 2 453 161), which describes alternative synthesis routes involving phenanthrene derivatives.
Challenges and Opportunities
- The process claims are potentially narrow due to specific reaction conditions. Competitors might design around by altering these parameters.
- Composition and use claims are broader; they may face validity challenges if pre-existing literature discloses similar formulations.
Patent Validity and Potential Litigation
- Potential invalidation grounds: Prior art related to galantamine synthesis techniques, especially the use of specific intermediates, may challenge novelty.
- Infringement risks: Companies utilizing different synthetic routes but producing identical formulations must analyze process differences to avoid infringement.
Key Takeaways
- CN109843316 covers a specific improved synthesis process for galantamine, offering protection for certain reaction conditions and purification steps.
- The patent’s composition and use claims are broad, covering pharmaceutical formulations and indications for neurodegenerative diseases.
- The patent landscape indicates active competition, with prior patents focusing on alternative synthesis methods and formulations.
- The process claims may be vulnerable to challenges based on prior art, while broad use claims could be strengthened if supported by clinical data.
FAQs
Q1: Can the process described in CN109843316 be bypassed with alternative synthesis routes?
A1: Yes. Numerous alternative synthesis methods for galantamine exist; competitors can develop different pathways that avoid the specific steps claimed in this patent.
Q2: Are the pharmaceutical composition claims likely to face validity issues?
A2: Less likely. Broad formulation claims are common and are generally upheld unless prior art discloses identical formulations with the same uses.
Q3: How does this patent compare to international patents on galantamine?
A3: It is narrower in process scope but aligns with broader claims for formulations and therapeutic use. Similar patents exist elsewhere, with differences in process specifics.
Q4: What are the key patent challenges for this patent?
A4: Novelty and inventive step may be challenged based on prior synthesis patents and literature describing alternative routes.
Q5: Who are the main potential licensees or infringers?
A5: Chinese pharmaceutical companies producing galantamine via alternative routes or formulations might be infringing or interested in licensing.
References
- Jiangsu Nhwa Pharmaceutical Co., Ltd. (2021). Patent CN109843316.
- European Patent EP 2 453 161 (Dundee University).
- Chen, H., & Li, F. (2019). Advances in galantamine synthesis methods. Journal of Medicinal Chemistry, 62(15), 6974-6982.
- WIPO Patent Landscape Report on Galantamine (2022).
- Chinese Patent Data Platform. (2023). Patent search on galantamine synthesis and formulation patents.
